Clinical Trial Update: BCMA-CD19 cCAR T for the Treatment of Refractory Lupus [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating BCMA-CD19 cCAR T therapy for refractory systemic lupus erythematosus and lupus nephritis, sponsored by iCell Gene Therapeu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• BCMA-CD19 cCAR T (BCMA-CD19 chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: iCell Gene Therapeutics | Conditions: Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING